Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|BIND-014||BIND-014 is a docetaxel-containing nanoparticle targeted to prostate-specific membrane antigen (PSMA) that gradually releases docetaxel, resulting in tumor cell death (PMID: 26847057, PMID: 31424909).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||BIND-014||Phase I||Actionable||In a Phase I clinical trial, BIND-014 treatment resulted in partial response in 10% (5/52) of patients with advanced solid tumors, and complete response in a cervical cancer patient (PMID: 26847057).||26847057|
|Unknown unknown||cervical cancer||not applicable||BIND-014||Phase I||Actionable||In a Phase I clinical trial, BIND-014 treatment resulted in a complete response in a cervical cancer patient (PMID: 26847057).||26847057|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT02479178||Phase II||BIND-014||A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck (iNSITE2)||Terminated|